A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 241
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ATII
Long Form : angiotensin II
No. Year Title Co-occurring Abbreviation
1975 Role of the C-terminal group for the biological activities of angiotensin. ---
1976 Characterization of angiotensin receptors in rabbit isolated atria. ---
1976 Preparation and characterization of adrenocortical plasma membrane angiotensin II receptors. ---
1977 Effects of angiotensins and catecholamines on the transmembrane potential and isometric force of rattib isolated atria. AP, AT-I
1978 Photoaffinity labeling of the angiotensin II receptor; pharmacology of the labeling peptides in the dark. ---
1980 Influence of sodium intake on catecholamine release by angiotensin and renal nerve stimulation in dogs. CA
1980 Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt (DOCA/salt). NA
1980 Vascular reactivity to angiotensin and noradrenaline in rats. Effect of aging and of uninephrectomy. NA
1980 Vascular reactivity to angiotensin and noradrenaline in spontaneously and renal hypertensive rats. NA, RHR, SHR
10  1984 Effect of natrium ionophore on aldosterone production in the rat adrenal gland. ---
11  1985 Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. RI
12  1985 Dopaminergic influence on the effects of angiotensin II in behavioural reactions. ---
13  1985 Effects of cardiopulmonary bypass and prostacyclin on plasma catecholamines, angiotensin II and arginine-vasopressin. AVP, CPB, NE
14  1986 Participation of angiotensin II in learning and memory. II. Interactions of angiotensin II with dopaminergic drugs. i.c.v, i.p
15  1986 Vasopressin induces breakdown of membrane phosphoinositides in adrenal glomerulosa and fasciculata cells. IP, VP
16  1986 [An effect of the intra-arterial infusion of angiotensin II in the chemotherapy of human hepatic cancer]. ---
17  1987 Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor. CDDP, IA, STS, TRC
18  1987 [Two-route chemotherapy using the anticancer drug cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate]. STS, TRC
19  1988 [Hepatic artery infusion chemotherapy with cisplatin and adriamycin in combination with angiotensin-II in the treatment of malignant liver tumors]. ADR, HCC, MLT, TAE
20  1988 [Selective augmenting effect of oxy-Hb on the contractions of cerebral arteries elicited by various vasoactive substances]. AA, DAG, HA, IDM, NCDC, OAG, oxyHb, PGF2 alpha, TXA2
21  1988 [Studies of intra-arterial hypertensive chemotherapy with cisplatin and peplomycin in advanced cancer of the uterine cervix--suitable dose of angiotensin II determined by intra-arterial digital subtraction angiography]. PEP
22  1989 "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats. BUN, DDP, STS, TRC
23  1989 Further evidence for the GABAergic influence on memory. Interaction of GABAergic transmission with angiotensin II on memory processes. i.c.v
24  1989 Neuropeptide Y-induced intracellular Ca2+ increases in vascular smooth muscle cells. BK, NPY
25  1989 [Changes of angiotensin II and angiotensin-converting enzyme in cor pulmonale with respiratory failure]. ACE, PRA
26  1989 [Hemodynamic changes and their relationship with the renin-angiotensin-aldosterone system in chronic obstructive pulmonary disease]. ALD, PAP, PRA, PVR, RAAS, RVP
27  1990 Effect of initial blood pressure level on cardiovascular reflexes caused by intraperitoneal neurotensin. BP, HR, i.p, NA, NTCS
28  1990 [Effect of captopril on the activities of angiotensin II and angiotensin converting enzyme during hypoxia induced pulmonary hypertension]. ACE, CO, PAP, PCWP, PRA, RVSWI
29  1990 [The hypertensive effect induced with angiotensin II and the physiological and pharmacokinetic aspects of two-route chemotherapy using CDDP and STS]. ---
30  1991 Effects of angiotensin II and angiotensin converting enzyme inhibitors on contractile and growth responses in isolated carotid arteries of the rat. ACE, AT-I, BrdUrd, CA, ET-1, WKY
31  1991 Neurokinins produce selective venoconstriction via NK-3 receptors in the rat mesenteric vascular bed. ACh, BK, EDRF, L-NNA, NA, NK-1, NKA, NKB, SP
32  1991 [5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II]. ---
33  1991 [Effect of captopril on hypoxia-induced pulmonary hypertension in pigs]. ACE, CO, PAP, PCWP, PRA
34  1992 Effects of angiotensin II on behavioral responses of defensive burying paradigm in rats. ---
35  1992 Effects of the new angiotensin-I-converting enzyme inhibitor imidapril on the responses of isolated vascular preparations to various agonists. ACE, AT-I, BK
36  1992 Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. ---
37  1992 [Plasma renin activity, angiotensin II, angiotensin converting enzyme, thromboxane A2 and prostacyclin I2 levels in pigs with severe hypoxia and hypercapnea and acidosis shock]. ACE, PAP, PRA
38  1992 [The clinical and pharmacokinetic evaluation of two-route chemotherapy with cisplatin and sodium thiosulfate in combination with angiotensin II]. STS
39  1993 Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. ---
40  1993 Duplex/colour Doppler sonography: measurement of changes in hepatic arterial haemodynamics following intra-arterial angiotensin II infusion. DCDS, HABF
41  1993 Hepatic arterial haemodynamics changes following intra-arterial angiotensin II infusion: duplex/colour Doppler sonography. DCDS, HABF
42  1993 Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys. ACE, AT-I, ECE, ET-1
43  1993 Tonic tone in arteries exposed continuously to angiotensin II in vitro. ---
44  1993 [Blood flow pattern and tumor vascular change following intraperitoneal administration of CDDP in VX2 ovarian tumor]. CDDP, i.p, Pt, STS
45  1993 [Changes in plasma neuropeptides before and after clonidine in patients with essential hypertension]. AVP, beta-EP, LEK, NT
46  1995 Effects of angiotensin II on brain monoamines in nonhypoxic and hypoxic mice. DA, ICV, acute, NE
47  1995 The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours. ---
48  1995 Vasoconstrictor peptides and cold intolerance in patients with stable angina pectoris. ET-1
49  1995 [Evaluation of the chemotherapy of a transplantable bladder tumour strain (NM-B-1) by two anti-cancer drugs in combination with a pressor agent in nude mice]. AML, TV
50  1995 [The significance of changes in plasma renin angiotensin aldosterone system and atrial natriuretic factor in patients with high altitude myocardial hypoxidosis]. ALD, ANF, HACC, HAMH, PRA
51  1996 Catecholamines, renin-angiotensin-aldosterone system, and atrial natriuretic peptide at rest and during submaximal exercise in patients with congestive heart failure. ANP, CHF, PRA, RAA
52  1996 Effect of angiotensin II on immunotoxin uptake in tumor and normal tissue. ---
53  1996 Effect of induced hypertension with angiotensin II infusion on biodistribution of 111in-labeled monoclonal antibody. ---
54  1996 Effects of angiotensin II on brain monoamine oxidase activity in non-hypoxic and hypoxic mice. i.c.v, MAO-B, MAOA
55  1996 Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. ET-1, MAP
56  1996 Relationship between some humoral factors and left ventricular hypertrophy in essential hypertension. ALD, EH, LVH, LVMI, PTH
57  1996 Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. ---
58  1996 Tetrandrine blocks voltage-dependent calcium entry and inhibits the bradykinin-induced elevation of intracellular calcium in NG108-15 cells. BK
59  1997 Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. ---
60  1997 Effects of angiotensin II on biogenic monoamine uptake in the brain of nonhypoxic and hypoxic mice. 5-HT, DA, i.c.v, NA
61  1997 Responses of catecholamines, renin-angiotensin system, and atrial natriuretic peptide to exercise in untrained men and women. ALD, ANP, NE
62  1997 [Effect of puerarin on plasma endothelin, renin activity and angiotensin II in patients with acute myocardial infarction]. AMI, ET, GIK, RA, RIA
63  1997 [Effects of coumarins from cnidium monnieri on the function of pituitary-adrenocortical axis in kidney yang deficiency rats]. ACTH, ALD, PCD, TCR
64  1997 [Effects of hypoxia and taurine on vasoconstriction peptides from cultured bovine pulmonary arterial endothelial cells]. EDF, ET-1, PAEC
65  1997 [The changes of intraerythrocyte calcium metabolism and their responses to nifedipine in patients with essential hypertension]. EH, PRA
66  1998 Age-related responses of vasoactive factors during acute exercise. AM, ANP
67  1998 Differential behavioral effects of angiotensin II microinjected unilaterally into the CA1 hippocampal area. ---
68  1998 Effects of a urinary trypsin inhibitor on acute circulatory insufficiency after surgical operation. ANP, ET-1, IL-8, NAG, PMNE, UTI
69  1998 Impaired endothelin-1 release in tilt-induced syncope. ET-1
70  1998 Persistent distension and enhanced diffusive extravasation of tumor vessels improved uniform tumor targeting of radioimmunoconjugate in mice administered with angiotensin II and kininase inhibitor. HSA, mAbs
71  1998 [The protective effect of captopril during myocardial ischemia and reperfusion and its mechanism]. CBF, CI, CPB, CPL, ET-1, MDA, RA
72  1999 Angiotensin II (ATII)-inducible platelet-derived growth factor A-chain gene expression is p42/44 extracellular signal-regulated kinase-1/2 and Egr-1-dependent and mediated via the ATII type 1 but not type 2 receptor. Induction by ATII antagonized by nitric oxide. AT1, PDGF, SMCs
73  1999 Effect of angiotensin II and telmisartan, an angiotensin1 receptor antagonist, on rat gastric mucosal blood flow. ---
74  1999 Enhanced effects of monoclonal antibody carboplatin immunoconjugates uptake and anti-tumor effects with angiotensin II and tumor necrosis factor. TNF
75  1999 Suppression of angiotensin II stimulated responses in aortic vascular smooth muscle cells of experimental cirrhotic rats. ECAR, VSMCs
76  1999 Systematic toxicological analysis procedures for acidic drugs and/or metabolites relevant to clinical and forensic toxicology and/or doping control. ACE, NSAIDs, STA
77  1999 [Kidney]. ---
78  2000 A comparison of intervention with losartan or captopril in acute myocardial infarction. ACE
79  2000 Angiotensin II-receptor antagonists: an overview. ACE, RAS
80  2000 Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans. ACE, RAS
81  2000 Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. mAb, RIT, Tq
82  2000 Plasma renin activities, angiotensin II concentrations, atrial natriuretic peptide concentrations and cardiopulmonary function values in dogs with severe heartworm disease. ANP, CS, PRA
83  2000 Plasma-levels of endothelin-1 and angiotensin-II and reactivity of arterial blood pressure to exogenous sympathomimetics and vasoactive peptides in rat model of malignant renal hypertension. ET-1
84  2000 The mechanism of the decrease in cytosolic Ca2+ concentrations induced by angiotensin II in the high K(+)-depolarized rabbit femoral artery. ---
85  2000 Use of angiotensin II stress pulsed tissue Doppler imaging to evaluate regional left ventricular contractility in patients with hypertrophic cardiomyopathy. HCM, LV, LVEF, PTDI, TVI
86  2000 [Observation on short-term effects of Angelica injection on chronic obstructive pulmonary disease patients with pulmonary hypertension]. COPD, EDF, ET-1, mPAP, PVR
87  2000 [Study on the relation between hypertensive left ventricular hypertrophy in very old people with neurohormonal factors and ventricular arrhythmias]. ALD, HF, INS, LF, LVH, REN, VLF
88  2000 [The impairment of Gq protein-coupled receptor in aortic vascular smooth muscle cells of cirrhotic rats]. ECAR, MAPK, VSMCs
89  2001 Angiotensin II receptor blockers for the treatment of hypertension. ACE, AT, CHF, ESRD, Val-HeFT
90  2001 Angiotensin-II and endothelin-1 levels in children with renoprival hypertension. ESRD, ET-1
91  2001 Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. ACE, alpha-SMA, CA, HSC, mRNA, PE, RAS
92  2001 Early changes of arginine vasopressin and angiotensin II in patients with acute cerebral injury. AVP
93  2001 Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. ACEI
94  2001 Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. ACE, UAER
95  2001 Endothelium-independent conversion of angiotensin I by vascular smooth muscle cells. ACE, AT-I, SMC
96  2001 Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes. ACE
97  2001 [A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with angiotensin-II and administration of tegafur/uracil]. CA19-9
98  2001 [Clinical study on conducting physical exercise in lowering blood pressure of hypertensive patients and influencing their endocrine hormones]. 6-k-PGF1 alpha, ANF, PRA
99  2002 Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Ac-HSC, ACE, HCC, PE, RAS, TIMP-1, VEGF
100  2002 Chronic effects of endothelin 1 and angiotensin II on gap junctions and intercellular communication in cardiac cells. Cx40, Cx43, ET-1, NRCs
101  2002 Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. MNCs, RAS, SBP, WT
102  2002 Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. ACE, CHF
103  2002 Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. ACE, PE, RAS, Retro-Tet, VEGF
104  2002 Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. ACE, BP
105  2002 Vasoactive peptides in a pulmonary embolism model. ANP, PAP, PE, RIA
106  2002 [The influence of nasal continual positive airway pressure on some vasoactive substances in patients with obstructive sleep apnea syndrome]. cAMP, cGMP, ET-1, nCPAP
107  2003 Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. ACE, AT1R, TGF-beta1
108  2003 Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. LDL
109  2003 Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. IRB, PRO
110  2003 Endothelin-1 and vasopressin plasma levels are not associated with the insertion/deletion polymorphism of the human angiotensin I-converting enzyme gene in patients with coronary artery disease. ACE, CAD, ET-1, RA, VP
111  2003 Intra-arterial infusion chemotherapy with angiotensin-II for locally advanced and nonresectable pancreatic adenocarcinoma: further evaluation and prognostic implications. ---
112  2003 Large A-V fistula: pathophysiological consequences and therapeutic perspectives. ACE, ANP, AVF, AVP, NO, RAS, SNS
113  2003 Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. ACE, NO
114  2003 Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. RAS
115  2003 Sex differences in the modulation of K+ currents in diabetic rat cardiac myocytes. ACE, ECE, ET-1, STZ
116  2003 The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ACE, HD, rHuEPO
117  2003 The renin-angiotensin-aldosterone system in patients with depression compared to controls--a sleep endocrine study. ACTH, AUC, HPA, MR, RAAS, REM
118  2003 [Diagnostic implications of detecting antibodies to angiotensin-converting enzyme and its substrates]. ACE, NAb
119  2003 [Hypertrophy and ventricular remodeling in systemic arterial hypertension: role of AT1 receptors]. ---
120  2004 Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. ACEIs, RAS, VEGF
121  2004 Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. DNP, MAP
122  2004 Effects of angiotensin II on rat pancreatic stellate cells. ERK, JNK, PSCs, RAS
123  2004 Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. ACE, DBP, SBP
124  2004 Prevention and treatment of stroke in patients with hypertension. ---
125  2004 Relationship between hypertensive left ventricular hypertrophy, neurohormonal factors and ventricular arrhythmias in very old patients. ALD, HF, INS, LF, LVH, PVC, REN, VLF
126  2004 The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. ACE, DGF
127  2004 The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. ACE, BP, LVH, RAAS
128  2004 [Changes of angiotensin II and its receptor during the development of chronic intermittent hypoxia-induced hypertension in rats]. AT1R, CIHO, IH, MAP, RA, SC
129  2004 [Hypertension and fluid volume increase in uremic patients treated with convective hemodialysis: electric bioimpedence analysis]. ACE, BP, CV, HD
130  2005 Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. ACEIs, ARBs, CHF, RAS
131  2005 Bioflavonoids effectively inhibit smooth muscle cell-mediated contraction of collagen matrix induced by angiotensin II. SMC
132  2005 Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. ACEI, IFN, PE
133  2005 Hypertension, antihypertensive treatment and stroke prevention. ---
134  2005 Teratogenicity with angiotensin II receptor antagonists in pregnancy. ACE
135  2005 The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. ARBs, GSI, OM
136  2005 The role of renin angiotensin system blockade in the treatment of atrial fibrillation. ACEI, AF, RAS
137  2005 [The changes of some vasoactive substances after operation in patients with obstructive sleep apnea-hypopnea syndrome]. ACA, ELISA, ET-1, OSAHS, PSG, TXB2
138  2006 A case of ACTH-independent bilateral macronodular adrenal hyperplasia and severe congestive heart failure. AIMAH, CHF, CS, MC2R
139  2006 Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. CDAA, HSC, PKC, VEGF
140  2006 Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution. IAC
141  2006 Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. ACE, ACEI, RAS
142  2006 Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome. ACE, RAS, SRINS
143  2006 Impaired drinking response in histamine H3 receptor knockout mice following dehydration or angiotensin-II challenge. H3Rs, i.c.v, RalphaMeHA
144  2006 Inducible platelet-derived growth factor D-chain expression by angiotensin II and hydrogen peroxide involves transcriptional regulation by Ets-1 and Sp1. PDGF-D, SMCs
145  2006 Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. ACE, RAS
146  2006 [In vitro effects of cAMP- and cGMP-stimulating drugs on the relaxation of the prostate smooth muscle tissue contraction induced by endothelin-1]. BPH, CNP, ET-1, LUTS, NNP, NO
147  2006 [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2]. 6MT, ACE-I, ALD, ARB, BNP, EF, HRV, NE, NH, PRA, QL
148  2006 [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)]. 6MT, ACE-I, ALD, ARB, BNP, CHF, EF, HRV, LV, NE, NH, PRA, QOL
149  2007 Angiotensin II receptor blocker inhibits neointimal hyperplasia through regulation of smooth muscle-like progenitor cells. AT2R, BM-MNCs, GFP, PB-MNCs, SM
150  2007 Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release. APC, AT1-R, ATR, HC, NC
151  2007 Aqueous humor dynamics in monkeys in response to the kappa opioid agonist bremazocine. BRE, IOP, MAP, nor-BNI
152  2007 Blockade of renin-angiotensin system in antifibrotic therapy. Ac-HSC, ACE, ARB, IFN, RAS, TGF-beta, TIMP-1
153  2007 Colchicine, a microtubule depolymerizing agent, inhibits myocardial apoptosis in rats. ---
154  2007 Different reactivity of the proximal and distal segments of the radial artery to vasoconstrictors in patients undergoing coronary artery bypass grafting. CABG, ET-3, PE, PGF2, RA
155  2007 Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk. AGT, AGTR1, HR
156  2007 Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor. BP, DSS, EOU, SON
157  2007 Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. ACEI, ARB, HCC, RAS, VEGF
158  2007 Reperfusion kinase phosphorylation is essential but not sufficient in the mediation of pharmacological preconditioning: Characterisation in the bi-phasic profile of early and late protection. ERK, PPC
159  2007 Time-dependent changes in pulmonary vascular responses to acute hypoxia during and after cold exposure in rats. ---
160  2008 1,4,5-Inositol trisphosphate-operated intracellular Ca(2+) stores and angiotensin-II/endothelin-1 signaling pathway are functional in human embryonic stem cell-derived cardiomyocytes. ET-1, hESC-CM
161  2008 Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide. ---
162  2008 The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. ACE, ATII-1a, EC, SBR
163  2009 Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype. IPH
164  2009 Cell-cell bond modulates vascular smooth muscle cell responsiveness to Angiotensin II. AT1R, Cav-1, VSMC
165  2009 Isolation and characterization of resident mesenchymal stem cells in human glomeruli. alpha-SMA, Gl-MSC, MSC, vWF
166  2009 Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. DL, PHE, STZ-rats
167  2009 Pals-associated tight junction protein functionally links dopamine and angiotensin II to the regulation of sodium transport in renal epithelial cells. PATJ
168  2009 Strain-dependent differences of restraint stress-induced hypertension in WKY and SHR. BP, HR, NE, SHR, TC, WKY
169  2010 Diuretics and diabetes incidence--an appeal against the reluctance to prescribe a medication that is safe and proven. ACE
170  2010 Human embryonic stem cell-derived cardiomyocytes can mobilize 1,4,5-inositol trisphosphate-operated [Ca2+]i stores: the functionality of angiotensin-II/endothelin-1 signaling pathways. ET-1, hESC-CM
171  2010 Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. ARBs, AT1-R, CNS, GM-CSF, IL-12, PD, RAS
172  2010 Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications. RAA
173  2010 The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. 4-HNE, BDL, CTGF, MMP-13, SMA, TGF-beta1, TIMP-1
174  2011 Angiotensin II Inhibits Insulin Binding to Endothelial Cells. IR
175  2011 Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs. HUVECs, NO
176  2011 Angiotensin II-mediated Nrf2 down-regulation: a potential causing factor for renal fibrosis? EMT, Nrf2
177  2011 Ectopic fat storage, insulin resistance, and hypertension. ACE, RAAS
178  2011 Impact of renin-angiotensin system in hepatocellular carcinoma. ACEI, ALD, BCAA, HCC, IFN, IR, RAS, SAB, VEGF, VK
179  2011 Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. ---
180  2011 Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. HR, NOS, SHR
181  2011 Suppression of Nrf2 signaling by angiotensin II in murine renal epithelial cells. alpha-SMA, ATF3, GCL, Nrf2, ROS
182  2011 The renin-angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D-resistance rickets (HVDRR). ACE, HVDRR, HVDRR, PRA, PTH, RAS, VDR KO
183  2011 The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis. BMP-5, EMT, TGF-ss, TNF-alpha
184  2011 [Multicenter trial of olmesartan. Main results]. ACE, OM
185  2011 [The significance of generic valsartan in the treatment of patients]. ARB, RAAS
186  2012 Angiotensin II protects primary rat hepatocytes against bile salt-induced apoptosis. ARBs, GCDCA, HSCs, TLC-S
187  2012 Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. CKD, LV, RAS
188  2012 Effect of inter-renal aortic coarctation-induced hypertension on function and expression of vascular alpha(1A)- and alpha(1D)-adrenoceptors. AC7, BMY, RS, SO
189  2012 Glomerular repair retardation via blocking of angiotensin II type 1a receptor pathway in a mouse glomerulonephritis model. HSV, VEGF
190  2012 On the different roles of AT1 and AT2 receptors in stretch-induced changes of connexin43 expression and localisation. AT-R, CMS, Cx43
191  2012 Relaxant effect of a water soluble carbon monoxide-releasing molecule (CORM-3) on spontaneously hypertensive rat aortas. CO, ET-1, NO, SHR, WKY
192  2012 Restoring nitric oxide cytosolic calcium regulation by cyclic guanosine monophosphate protein kinase I alpha transfection in coronary endothelial cells of spontaneously hypertensive rats. GMP, NO, SHR, WKY
193  2013 Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. IFN-gamma, NK, T-bet
194  2013 CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. CD40L, FACS, ROS
195  2013 Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. Ac-HSC, MyD88, NF-kappaB, TGF-beta, TLR4
196  2013 Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Ac-HSC, CDAA, DRI, GST-P, NASH, RAS, TGF-beta1, VEGF
197  2013 Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Ac-HSC, ACEI, ALD, CDAA, GST-P, SAB
198  2013 No evidence for the expression of renin-angiotensin-aldosterone system in otosclerotic stapes footplates. ACE, AT-IIR, HE, IFA, RAA, SNP
199  2013 Peroxisome proliferator-activated receptor gamma, coactivator 1alpha deletion induces angiotensin II-associated vascular dysfunction by increasing mitochondrial oxidative stress and vascular inflammation. PGC-1alpha
200  2013 Thirst response to acute hypovolaemia in healthy women and women prone to vasovagal syncope. LBNP, VVS
201  2014 Improved gastric emptying in diabetic rats by irbesartan via decreased serum leptin and ameliorated gastric microcirculation. DG, ET, GER, NOS
202  2014 Interference of angiotensin II and enalapril with hepatic blood flow regulation. HABR
203  2014 Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction. MI
204  2014 Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. MAP
205  2014 Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. eNOS, mPTP, mtROS, NOX
206  2014 Obligatory role of intraluminal O2- in acute endothelin-1 and angiotensin II signaling to mediate endothelial dysfunction and MAPK activation in guinea-pig hearts. ET-1, NOX, XO
207  2014 The effect of intra-arterial angiotensin II on the hepatic tumor to non-tumor blood flow ratio for radioembolization: a systematic review. ---
208  2014 Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice. DRI, FLS, NASH, PRA, RAS
209  2015 A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. HF, LV
210  2015 Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas. IHs, VEGF
211  2015 Losartan reduces oxidative damage to renal DNA and conserves plasma antioxidant capacity in diabetic rats. 8-oxodGuo, Adp, FRAP, ROS, STZ
212  2015 Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery. BCa, MALDI
213  2015 The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome. hCG, OHSS, PCOS, VEGF
214  2015 [Vascular reactivity and receptor expression of endogenous vasoconstrictor in rats with alcoholic cardiomyopathy and insulation stress]. AVP, ET-1, GR, NA
215  2016 Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. Ac-HSC, CDAA, LPS, NASH, TGF, UDCA, ZO-1
216  2016 Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk. ---
217  2016 PGC-1alpha dictates endothelial function through regulation of eNOS expression. ERRalpha, PGC-1alpha
218  2016 Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors. AT-I, CES1, CHF, CIs, LSM
219  2016 Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma. ACE, IH, PRA, RAS
220  2017 Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. FMD, HAECs, IHE, ROS
221  2017 Aldosterone-Sensing Neurons in the NTS Exhibit State-Dependent Pacemaker Activity and Drive Sodium Appetite via Synergy with Angiotensin II Signaling. SFO
222  2017 Enhanced peripheral dopamine impairs post-ischemic healing by suppressing angiotensin receptor type 1 expression in endothelial cells and inhibiting angiogenesis. AT1R, HLI, RAS
223  2017 Redox regulation of cardiovascular inflammation - Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species. ---
224  2017 [Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension]. ACE, CHD, ET-1, FC, IL, RAAS
225  2018 A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock. FDA
226  2018 Action Potential Prolongation, beta-Adrenergic Stimulation, and Angiotensin II as Co-factors in Sarcoplasmic Reticulum Instability. AP, APD, CMs, ISO, ISO, ITI, SR
227  2018 alpha1AMPK deletion in myelomonocytic cells induces a pro-inflammatory phenotype and enhances angiotensin II-induced vascular dysfunction. AMPK, CCR2
228  2018 Angiotensin II Brings More Questions Than Answers. ---
229  2018 Angiotensin II Use in Refractory Multisystem Shock: A Case Report. ED, ICU
230  2018 Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. ARBs, CCA, YAP
231  2018 Clinical significance of increased urotensin II levels in acute myocardial infarction. AMI, MMP-2, NT-BNP, PCI, UII
232  2018 Crosstalk between FGF23- and angiotensin II-mediated Ca2+ signaling in pathological cardiac hypertrophy. FGF23, HF, LVH, NRVMs, RAAS
233  2018 Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes. BRV, DADs, EB, HCM, iPSC
234  2018 The Angiotensin II Type 1 Receptor Antagonist Losartan Affects NHE1-Dependent Melanoma Cell Behavior. AT1, AT2, NHE1
235  2018 The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress. ACEIs, ARIs, AT, CRC, IGF-1, miRs, VEGF
236  2019 A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock. ---
237  2019 Angiotensin II in septic shock. ---
238  2019 Angiotensin II: A New Vasopressor for the Treatment of Distributive Shock. ---
239  2019 Profibrotic effects of angiotensin II and transforming growth factor beta on feline kidney epithelial cells. alpha-SMA, AT1, CRFK, CTGF, EMT, TGF-beta1, TN-C, TSP-1
240  2020 Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1. AAC, EndMT, MCECs, RXFP1
241  2020 Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. DM2, SGLT2I